Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

19.23 -0.46 (-2.34%)
Streaming Delayed Price Updated: 2:43 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗
 
Via Benzinga
News headline image
Expert Ratings for Denali Therapeutics ↗
 
Via Benzinga
News headline image
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022 ↗
 
Via Benzinga
News headline image
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday ↗
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Denali Therapeutics Announces Proposed Offering of Common Stock
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Netflix, Biogen And Other Big Gainers From Wednesday ↗
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
News headline image
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still... 
Via FinancialNewsMedia
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗
Upgrades 
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
News headline image
4 Undervalued Biotech Stocks to Add to Your Buy List ↗
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
Via InvestorPlace
News headline image
AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship ↗
Flagship Pioneering is swiping one of AbbVie's biggest names. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia... 
Via FinancialNewsMedia
News headline image
7 F-Rated Stocks to Avoid During the Downturn ↗
It's easy to find hard hit stocks in this market, but what's harder to determine is which stocks are truly F-rated stocks among the losers. 
Via InvestorPlace
News headline image
Denali Receives Formal Letter Regarding FDA Hold On Alzheimer's Potential Program ↗
As previously announced, Denali Therapeutics Inc (NASDAQ: DNLI) was informed via e-mail communication from the FDA that DNL919 (ATV:TREM2) Investigational New Drug (IND... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.